The purpose of this study is to evaluate whether treatment with RP2 can provide efficacy as 2L treatment combined with atezolizumab plus bevacizumab in patients with locally advanced unresectable, recurrent, and/or metastatic HCC.
Hepatocellular Carcinoma
The purpose of this study is to evaluate whether treatment with RP2 can provide efficacy as 2L treatment combined with atezolizumab plus bevacizumab in patients with locally advanced unresectable, recurrent, and/or metastatic HCC.
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC
-
Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States, 14203
University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, United States, 19104
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States, 15232
The West Clinic, Germantown, Tennessee, United States, 38138
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Replimune Inc.,
Shaheen Kumar, MD, STUDY_CHAIR, Replimune Inc.
2028-07-01